SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:oru-108884"
 

Sökning: id:"swepub:oai:DiVA.org:oru-108884" > A European Cost-Uti...

A European Cost-Utility Analysis of the MiniMedTM 780G Advanced Hybrid Closed-Loop System versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes

Jendle, Johan, 1963- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper
Buompensiere, Maria Ida (författare)
Medtronic International Trading Sarl, 30907, Tolochenaz, Vaud, Switzerland
Ozdemir Saltik, Asli Zeynep (författare)
Medtronic, Market Access & Reimbursement, Saray Mh. Esnaf Sk. Akkom Ofis Park Laodik Plaza, No:2 Kat:3-4 Umraniye, Istanbul, Turkey
visa fler...
de Portu, Simona (författare)
Medtronic International Trading S?rl, Rte du Molliau 31, Tolochenaz, Switzerland
Smith-Palmer, Jayne (författare)
Covalence Research Ltd, 555181, Rivers Lodge, West Common, Harpenden, United Kingdom of Great Britain and Northern Ireland
Pollock, Richard (författare)
Covalence Research Ltd, 555181, Harpenden, United Kingdom of Great Britain and Northern Ireland
Cohen, Ohad (författare)
Medtronic International Trading Sàrl, Toluchenaz, Tolochenaz, Switzerland
visa färre...
 (creator_code:org_t)
Mary Ann Liebert, 2023
2023
Engelska.
Ingår i: Diabetes Technology & Therapeutics. - : Mary Ann Liebert. - 1520-9156 .- 1557-8593. ; 25:12, s. 864-876
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Advanced hybrid closed-loop (AHCL) automated insulin delivery systems are the most effective therapy in terms of assisting people with type 1 diabetes (T1D) to achieve glycemic targets; however, the cost can represent a barrier to uptake. Here, a cost-utility analysis of the MiniMedTM 780G AHCL system (MM780G) versus intermittently-scanned continuous glucose monitoring (is-CGM) plus multiple daily insulin injections (MDI) in people with T1D not achieving glycemic goals was performed across six European countries.Methods: Clinical input data were sourced from the ADAPT trial. Assuming a baseline HbA1c of 9.04%, HbA1c reductions of 1.54% for AHCL and 0.2% for is-CGM+MDI were assumed. The analyses were performed from a payer perspective over a time horizon of 40 years and an annual discount rate of 3% was applied.Results: Across all countries, the use of AHCL was projected to result in an incremental gain in quality-adjusted life expectancy of >2 quality-adjusted life years (QALYs) versus is-CGM+MDI. Lifetime direct costs were higher with AHCL resulting in incremental cost-utility ratios for AHCL versus is-CGM+MDI ranging from EUR 11,765 per QALY gained in Austria to EUR 43,963 per QALY gained in Italy.Conclusions: For people with T1D managed with is-CGM+MDI not achieving glycemic targets, initiation of the MM780G system was projected to improve long-term clinical outcomes; however, due to differences in healthcare costs between countries, the health economic outcomes differ. In the countries included here, AHCL is likely to be cost-effective relative to is-CGM+MDI for people not achieving glycemic goals with is-CGM+MDI. The ADAPT trial is registered with ClinicalTrials.gov, NCT04235504.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Type 1 diabetes
Automated insulin delivery
Costs and cost analysis

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy